No Data
No Data
Elicio Therapeutics On May 23 Announced Preliminary Data From Ongoing AMPLIFY-7P Phase 1a Study Of ELI-002 7P In Patients With MKRAS-Driven Solid Tumors At 2024 ASCO Annual Meeting
ELI-002 7P administered as a monotherapy was well tolerated and able to generate a ~100x mKRAS-specific expanded T cell response relative to baseline levelsELI-002 7P generated an mKRAS-specific T cel
Express News | Elicio Therapeutics: Eli-002 7P Was Well Tolerated With T Cell Responses Correlating With a Reduction in Tumor Biomarkers at Recommended Phase 2 Dose
Express News | Elicio Therapeutics Inc: Eli-002 7P Administered as a Monotherapy Was Well Tolerated
Express News | Elicio Therapeutics Announces Preliminary Data From the Ongoing Amplify-7P Phase 1a Study of Eli-002 7P in Patients With Mkras-Driven Solid Tumors at the 2024 Asco Annual Meeting
H.C. Wainwright Maintains Elicio Therapeutics(ELTX.US) With Buy Rating, Maintains Target Price $10
H.C. Wainwright analyst Robert Burns maintains $Elicio Therapeutics(ELTX.US)$ with a buy rating, and maintains the target price at $10.According to TipRanks data, the analyst has a success rate of 24.
HC Wainwright & Co. Reiterates Buy on Elicio Therapeutics, Maintains $10 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates Elicio Therapeutics (NASDAQ:ELTX) with a Buy and maintains $10 price target.
No Data